Industry
Medical - Diagnostics & Research
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Insights
June 19, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Newsdesk
May 30, 2024 | 9:01 pm
Portfolio Pulse from Benzinga Newsdesk
May 29, 2024 | 8:32 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 11:07 am
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 10:42 pm
Portfolio Pulse from Benzinga Newsdesk
May 03, 2024 | 11:13 am
Portfolio Pulse from Benzinga Newsdesk
May 03, 2024 | 10:56 am
Portfolio Pulse from Benzinga Newsdesk
May 02, 2024 | 9:35 pm
Portfolio Pulse from Benzinga Newsdesk
May 02, 2024 | 8:33 pm
Portfolio Pulse from Benzinga Newsdesk
April 04, 2024 | 8:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.